Comparative effectiveness of tocilizumab vs standard care in patients with severe COVID-19-related pneumonia: a retrospective cohort study utilizing registry data as a synthetic control
Abstract Background The severity of coronavirus disease 2019 (COVID-19) infections has led to the development of several therapeutic agents, with tocilizumab becoming increasingly used to treat patients with COVID-19-related pneumonia. This study compared the use of tocilizumab treatment with the st...
Main Authors: | Yukari Uemura, Ryoto Ozaki, Tomohiro Shinozaki, Hiroshi Ohtsu, Yousuke Shimizu, Kazuo Izumi, Sho Saito, Nobuaki Matsunaga, Norio Ohmagari |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-12-01
|
Series: | BMC Infectious Diseases |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12879-023-08840-6 |
Similar Items
-
Comparison of Tocilizumab and Anakinra in the Treatment of COVID-19: A Single-Center Experience
by: Bengisu Pınar Acat, et al.
Published: (2022-08-01) -
Serum Lactate Dehydrogenase Level One Week after Admission Is the Strongest Predictor of Prognosis of COVID-19: A Large Observational Study Using the COVID-19 Registry Japan
by: Sho Nakakubo, et al.
Published: (2023-03-01) -
Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry
by: Dimitrios A. Pappas, et al.
Published: (2020-03-01) -
The effect of tocilizumab administration on inflammatory markers in COVID-19 patients
by: Engy Mohamed Riyad Soliman, et al.
Published: (2024-08-01) -
Tocilizumab: A potent immunomodulatory agent in the treatment of COVID-19 pneumonia
by: Sameer Bansal, et al.
Published: (2021-01-01)